TLPH: Talphera Corp Forward P/S Multiple

Official company branding of Talphera Corporation (TLPH)

Talphera, Inc. (TLPH) is introducing Naryf closed-loop dosing systems into the hospital IT sector, although revenue is currently absent due to the clinical testing stage and dependence on FDA approval. The expected price-to-sales ratio confirms valuation volatility, where the 1451.40 metric indicates the status of the current market consensus. Limited clinic budgets and pressure from traditional treatment methods remain the primary barriers.

TLPH Talphera: Price-to-Projected Revenue Ratio in the range 02/21/2024 - 05/14/2026

Comprehensive metric breakdowns and analytics for Talphera Corporation (TLPH)

- stock price and consensus target price:
Stock Quotes Talphera|TLPH - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Talphera Corporation|TLPH - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Talphera|TLPH - Company Book Value|Market Value to Book Value Ratio talphera.com|TLPH - Total Asset Value of Company
- issuer credit burden and liquidity indicators:
Total Debt to Capital Talphera, Inc.|TLPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Talphera, Inc.|TLPH - Company Cumulative Debt|Debt to Book Capitalization Ratio Talphera Corporation|TLPH - Company Long-Term Loans and Borrowings|Company Short-Term Debts Talphera|Quick Liquidity Indicator talphera.com
- business earnings and investment ratios data:
TLPH - Final Profit|Projected Future Earnings Talphera, Inc.|TLPH - Business Payback Period|Future Price to Earnings Talphera Corp|TLPH - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Talphera Corporation|TLPH - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Talphera|TLPH - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months talphera.com|TLPH - Net earnings per one share growth for the current year|Net earnings per share growth forecast for next year Talphera, Inc.
- sales revenue and business income indicators:
TLPH - Company Revenue|Company Projected Revenue Talphera|TLPH - Price-to-Sales Ratio|Forward P/S Multiple Talphera Corporation
Initial company analysis:TLPH (Talphera)
Product sample of Talphera Corporation

The implementation of Talphera, Inc. (TLPH) pain management systems in surgical centers directly impacts the forward price-to-sales ratio, reflecting market expectations for the monetization of new devices. This indicator compares current market capitalization with projected annual sales volume, allowing investors to assess the premium paid for future growth and the risks of failing to meet target revenue benchmarks.

Key competitors

Gilead Sciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CDTX (Cidara Therapeutics Corp)|Novavax Corp - Forward P/S Multiple|CVAC - Forward P/S Multiple|Valneva SE (VALN) - Price-to-Projected Revenue Ratio|VIR (vir.bio) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio SIGA Technologies|Emergent BioSolutions Inc - Future Price to Revenue|Forward P/S Multiple AVIR|IVVD (invivyd.com) - Forward Price to Sales|Forward P/S Multiple ENTA (Enanta Pharmaceuticals)|inovio.com (INO) - Market Cap to Future Revenue Ratio|HLVX - Price-to-Projected Revenue Ratio|Forward Price to Sales KLRS (Kalaris Therapeutics Inc.)|DYAI: Forward P/S Multiple|NanoViricides (NNVC) - Forward P/S Multiple|Forward Price-to-Revenue Multiple COCP|TRAW: Forward Price to Sales|Forward P/S Multiple DWTX|Market Cap to Expected Sales Ratio Qualigen Therapeutics Inc|Price-to-Projected Revenue Ratio AlloVir ALVR|VBIV: Market Cap to Projected Revenue|Virios - Forward P/S Multiple|Vaxart, Inc. (VXRT) - Forward Price-to-Revenue Multiple